Palonosetron Onkovis Qilu Pharma Spain

Palonosetron, the active ingredient in Palonosetron Onkovis Qilu Pharma Spain, is a 5‑HT3 receptor antagonist presented as a sterile injectable solution for intravenous use. It is employed to prevent nausea and vomiting associated with chemotherapy and postoperative settings in adult patients. GNH USA supplies Palonosetron Onkovis Qilu Pharma Spain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Palonosetron Onkovis Qilu Pharma Spain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and oncology centres worldwide.

Palonosetron is indicated for the prevention of nausea and vomiting related to chemotherapy and surgery. It acts on the serotonergic pathway to reduce emetic signals. - Chemotherapy‑induced nausea and vomiting (CINV): Provides long‑lasting protection against acute and delayed phases of CINV. - Post‑operative nausea and vomiting (PONV): Reduces the incidence of nausea and vomiting after general anesthesia. - Radiotherapy‑induced nausea and vomiting: Helps mitigate nausea associated with radiation treatment.

Palonosetron is generally well‑tolerated, but adverse reactions can occur.

Common Side Effects: - Headache  - Constipation  - Fatigue  - Diarrhea  - Dizziness  - Injection site erythema 

Serious or Rare Side Effects: - Severe hypersensitivity reactions (anaphylaxis, angio‑edema) - Prolonged QT interval on electrocardiogram  - Serotonin syndrome  - Cardiac arrhythmias  - Severe constipation or intestinal obstruction  - Neuro‑muscular weakness resulting t t t 

When ​​​  ​       ​     ​     …  ​  … …  …  …  … …  … 

    t  ... ...